The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals.

The article presents a study which examines the effectiveness of nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimes among antiretroviral-naive patients who are undergoing highly active antiretroviral therapy (HAART). The study analyzed the data of 994 antiretroviral-naive patients who were taking efavirenz and nevirapine with dual-nucleoside analogue backbones. It reveals no significant differences between efavirenz and nevirapine on the success and failure of the treatment.